Publications by authors named "Axel Gschwind"

Claim this Profile
A
Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and mutation.
Julia Forschner, Julia Huynh, Christopher Schroeder, Sorin Armeanu-Ebinger, Olga Seibel-Kelemen, Axel Gschwind

Front Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AI Model for Predicting Anti-PD1 Response in Melanoma Using Multi-Omics Biomarkers.
Axel Gschwind, Stephan Ossowski

Cancers (Basel)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biallelic MAD2L1BP (p31comet) mutation is associated with mosaic aneuploidy and juvenile granulosa cell tumors.
Ghada M H Abdel-Salam, Susanne Hellmuth, Elise Gradhand, Stephan Käseberg, Jennifer Winter, Axel Gschwind

JCI Insight· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
UV-radiation and MC1R germline mutations are risk factors for the development of conventional and spitzoid melanomas in children and adolescents.
Alexandra Liebmann, Jakob Admard, Sorin Armeanu-Ebinger, Hannah Wild, Michael Abele, Axel Gschwind

EBioMedicine· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients.
Michael Menzel, Stephan Ossowski, Sebastian Kral, Patrick Metzger, Peter Horak, Axel Gschwind

NPJ Precis Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse.
Suzana Mittelstadt, Olga Kelemen, Jakob Admard, Axel Gschwind, André Koch

Br J Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
Julia Eckardt, Christopher Schroeder, Peter Martus, Sorin Armeanu-Ebinger, Olga Kelemen, Axel Gschwind

J Cancer Res Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system.
Mirjam Renovanz, Sylvia C Kurz, Johannes Rieger, Bianca Walter, Hannes Becker, Axel Gschwind

Neurooncol Adv· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches.
Cristiana Roggia, Sorin Armeanu-Ebinger, Axel Gschwind, Olga Seibel-Kelemen, Sonja Hertler

Eur J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients.
Franz J Hilke, Tobias Sinnberg, Axel Gschwind, Heike Niessner, German Demidov

Cancers (Basel)· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma.
Andrea Forschner, Franz-Joachim Hilke, Irina Bonzheim, Axel Gschwind, German Demidov

Cancers (Basel)· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis